Literature DB >> 16953436

Vaccination against prostate cancer using a live tissue factor deficient cell line in Lobund-Wistar rats.

Julie E Heinrich1, Morris Pollard, William A Wolter, Zhong Liang, Hui Song, Elliot D Rosen, Mark A Suckow.   

Abstract

Reducing expression of the tissue factor gene in prostate adenocarcinoma cells (PAIII) results in a cell line that, in vivo, mimics the growth of wildtype (wt) PAIII. However, instead of continuing to grow and metastasize as wt PAIII tumors do, tissue factor deficient PAIII (TFD PAIII) masses spontaneously regress after several weeks. Although whole cell vaccines are typically inactivated prior to administration to prevent proliferation within the host, numerous studies have suggested that exposure to live, attenuated, whole tumor cells, and the extracellular microenvironment they recruit, increases immunotherapeutic potential. Here, we provide support for this notion, and a strategy through which to implement it, by demonstrating that subcutaneous vaccinations with the TFD PAIII protect the Lobund-Wistar rat against subsequent wt PAIII cell challenge. TFD PAIII immunized rats suffered significantly less metastasis of wt PAIII challenge tumors compared to unvaccinated naïve controls rats. These results offer the intriguing possibility that the TFD PAIII vaccine is an effective system for the prevention and, possibly, the treatment of prostate cancer.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16953436     DOI: 10.1007/s00262-006-0223-x

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  2 in total

1.  Rat prostate tumors express cancer procoagulant, an activator of coagulation factor X.

Authors:  Malgorzata Kamocka; Morris Pollard; Mark Suckow; Wojciech P Mielicki; Elliot D Rosen
Journal:  Comp Med       Date:  2008-06       Impact factor: 0.982

Review 2.  Pathogenesis, clinical and laboratory aspects of thrombosis in cancer.

Authors:  Massimo Franchini; Martina Montagnana; Giovanni Targher; Franco Manzato; Giuseppe Lippi
Journal:  J Thromb Thrombolysis       Date:  2007-03-31       Impact factor: 5.221

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.